Connect with us

Health

From Dubai to Malawi: How ‘Dr Knee’ is helping a nation take its first steps toward pain-free living

Published

on

Spread the love

In January, something extraordinary will unfold in Malawi, one of the world’s least developed countries, where knee specialists simply don’t exist, and where thousands live with chronic pain they’ve quietly carried for years. For many Malawians, the idea of walking without discomfort has long felt like a distant dream.

That may finally begin to change.

Dr Azam Badar Khan, better known across Dubai as “Dr Knee”, is returning to Malawi to lead the country’s first-ever knee surgery camp, bringing hope to patients who’ve never had access to this kind of care. And for the surgeon who has been working in Dubai’s top hospitals for more than 20 years, this mission is personal.

“When you meet someone who has lived with pain for 20 years and tells you they’ve simply ‘learned to manage,’ it stays with you,” Dr Knee said. “This camp is about giving them back the ability to move, work, dance, and live.”

A Country Where Knee Pain Is a Life Sentence

Last December, Dr Knee travelled across Blantyre and the capital, Lilongwe, where he examined more than 400 patients in just four days. The cases told the story of a nation battling what he calls a “silent epidemic of mobility loss.”

From severe osteoarthritis to injuries left untreated for decades, nearly every patient had one thing in common: There was nowhere to go for help.

Malawi, home to more than 21 million people, has no dedicated knee surgeon and limited orthopaedic services. Many people rely on makeshift support, living each day with grinding pain.

A Camp That Could Change Everything

In January, that begins to shift. Over six days, Dr Knee and his team will perform advanced procedures, from total knee replacements to corrective surgeries, at LMJ Hospital in Blantyre and LSF Hospital in Lilongwe.

Regional health officials say the impact could be transformational, not just for the patients, but for the country’s entire healthcare system.

Skill-sharing with local doctors, new treatment pathways, training programmes, all of it could plant the seeds for Malawi’s first real orthopaedic network.

Why Dubai Matters

Behind this mission is a city that has quietly become a launchpad for global medical outreach: Dubai.

“Dubai gave us the reach to scale a mission that started with a simple idea, helping people walk pain-free for longer,” Dr Knee said.

With its international connectivity and innovation-driven healthcare sector, the emirate has helped turn Dr Knee’s mobility mission into a cross-border movement spanning Africa, Asia, and soon even more regions.

A Blueprint for a Continent

The Malawi mission is only the beginning. Talks are already underway with health authorities in Zambia, Zimbabwe, Mozambique, and Uganda to develop broader mobility care programmes.
Back in the UAE, Dr Knee is also preparing for his first Dubai edition of the “Walk Again with Dr Knee” campaign this February, a project focused on early diagnosis, public awareness, and accessible joint care.

“We’re building a network of mobility care across continents,” he said. 

“Every step we take in one country helps strengthen the next.”

For patients in Malawi, those steps could soon feel lighter, and, for many, pain-free for the first time in their lives.

With over 35 years of experience in journalism, copywriting, and PR, Michael Gomes is a seasoned media professional deeply rooted in the UAE’s print and digital landscape.

Health

UAE to abolish health card: Emirates ID to replace it at hospitals

Published

on

Spread the love

In a major digital shift, Emirates Health Services (EHS) has begun implementing a plan to abolish the health card, replacing it with the Emirates ID as the primary identifier for patients across its hospitals and healthcare centres.

The move is aimed at simplifying access to treatment and cutting administrative red tape.

What’s changing?

For years, patients needed a valid health card to register and receive treatment at EHS facilities, including renewals when expired.

Under the new system:

  • The Emirates ID will serve as the unified patient identifier
  • No separate health card will be required
  • Registration procedures will be streamlined
  • Administrative steps will be reduced

The aim? Faster access, shorter waiting times and smoother admissions.

Who will benefit first?

According to EHS, the rollout will happen in phases.

Phase One:

  • Emirati citizens
  • UAE residents
  • Nationals of GCCcountries

Later phases will include:

  • Children of Emirati women
  • Spouses of Emirati citizens
  • People of determination
  • Additional categories requiring coordination with other entities

Saif Abdullah Al Hassani, Head of Service Development and User Experience at EHS, said the move aligns with the UAE’s digital transformation agenda and national database integration.

In simple terms: one ID, one system, less paperwork.

EHS confirmed it is technically ready to cancel the health card for all groups immediately. However, a phased rollout is being adopted to monitor system performance and address any operational challenges before full implementation.

When will it be fully implemented?

The first group of beneficiaries has already completed technical and regulatory preparations, with a formal announcement expected soon.

Further categories will be added gradually as coordination with external entities is completed.

What this means for patients

Once fully implemented:

  • No more renewing health cards
  • Faster registration at hospitals
  • Reduced paperwork
  • Improved patient experience

Continue Reading

Business

UAE announces new pharmaceutical law to end medical product monopoly

Published

on

Spread the love

The Emirates Drug Establishment (EDE) has activated a new regulatory mechanism aimed at ending monopolistic practices in the UAE’s medical product market, marking a significant shift in how pharmaceuticals are distributed across the country.

Introduced under the 2024 federal law governing medical products, pharmacists and pharmaceutical establishments, the measure requires pharmaceutical companies to appoint more than one authorised agent for each medical product marketed in the UAE.

Officials say the move is designed to strengthen pharmaceutical security, ensure stable medicine supplies and enhance national preparedness during emergencies.

Ending single-agent control

Under the new framework, companies can no longer depend on a single distributor for a specific product.

By mandating multiple authorised agents, the EDE aims to:

  • Prevent supply disruptions
  • Improve distribution efficiency
  • Increase supply-chain flexibility
  • Eliminate monopolistic control over essential medicines

The authority said the mechanism will widen treatment options and promote healthier competition among distributors, ultimately benefiting patients and healthcare providers.

Boosting investment and market sustainability

Beyond addressing monopolies, the initiative is expected to make the UAE pharmaceutical sector more attractive to investors.

Officials note that diversified distribution channels reduce operational risks and enhance long-term sustainability, a key pillar in building a resilient healthcare ecosystem.

The reform aligns with the UAE’s broader strategy to modernise regulatory systems and position the country as a regional hub for life sciences and pharmaceutical trade.

Saeed bin Mubarak Al Hajeri, Minister of State and Chairman of the EDE’s Board of Directors, said the initiative reflects the UAE’s public policy approach to developing a robust national pharmaceutical ecosystem.

He emphasised the authority’s commitment to:

  • Diversifying supply chains
  • Enhancing regulatory efficiency
  • Creating a flexible legislative environment
  • Protecting public health

Officials stress that the mechanism goes beyond market competition. It serves as a strategic safeguard to ensure uninterrupted access to medicines during global disruptions or health emergencies.

What it means for the healthcare sector

The activation of the mechanism signals a transition toward a more competitive, transparent and secure pharmaceutical market.

  • For patients: Greater consistency in medicine availability
  • For distributors: Increased competition and operational flexibility
  • For investors: A stronger, more sustainable regulatory environment

As implementation of the 2024 federal law continues, further refinements are expected to shape the future of the UAE’s pharmaceutical supply chain and reinforce national health security.

Continue Reading

Health

Health alert: UAE issues warning after drug authority withdraws supplements over safety concerns

Published

on

Spread the love

Residents across the UAE have been urged to immediately stop using several health supplements and a laboratory product after the Emirates Drug Establishment (EDE) ordered their withdrawal from the market.

In four urgent circulars, the regulator announced the recall and ban of three food supplements and one medical product, citing safety concerns including unapproved ingredients, contamination risks and quality defects. The authority warned consumers not to purchase the named products, particularly through online sales platforms.

Businesses have also been instructed not to advertise, distribute, store or sell the affected items in pharmacies, medical warehouses, health shops or via e-commerce channels in the UAE.

Products that residents are advised to avoid

In its first alert, the EDE warned against an unauthorised supplement marketed as “Super Immune+”, stating that it contains unapproved ingredients, including dimethylaminoethanol (DMAE), molybdenum amino acid chelate, and boron citrate. The product was neither registered nor legally imported into the UAE.

A second circular ordered the withdrawal of WoundVite”, sold under the brand ZEN NUTRIENTS, after authorities identified the presence of a novel food ingredient not authorised under European regulations. The supplement had not undergone regulatory assessment in the UAE.

In a third notice, the EDE referenced a safety update issued by the U.S. Food and Drug Administration (FDA), coordinating with disease control authorities, regarding the recall of certain batches of “Rosabella Moringa Capsule” due to potential Salmonella contamination.

Separately, specific batches of the laboratory product “Isotonac-4” were recalled following a reported quality defect. The manufacturer and supplier have been instructed to implement an immediate withdrawal.

Public advisory

The EDE urged residents to verify the registration status of supplements and medical products before purchase and to avoid buying unverified health products from unofficial online sellers.

Consumers who have purchased any of the named items are advised to discontinue use immediately and consult a healthcare professional if they experience any adverse effects.

Authorities continue to monitor the market to ensure consumer safety and prevent the circulation of unauthorised health products.

Continue Reading

Popular

Exit mobile version
https://headline.ae/